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http://dx.doi.org/10.1016/j.jfma.201Hemorrhage is one of the hallmarks of dengue hemorrhagic fever. However, the mechanisms
that cause hemorrhage are unclear. In this review we focus on the possible factors that may
be involved in the disturbance of coagulation and fibrinolysis during dengue virus (DENV) infec-
tion. Factors such as autoantibodies and cytokines induced by DENV infection as well as hemo-
static molecules expressed on DENV-infected cells, and DENV viral proteins may all contribute
to the defect of hemostasis during DENV infection. It is the combination of these viral and host
factors that may tilt the balance of coagulation and fibrinolysis toward bleeding in dengue
patients.
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Blood coagulation (hemostasis) is a very delicately
balanced system that is tightly regulated by many different
mechanisms to prevent hemorrhage or clotting under
normal condition. Hemostasis consists of primary and
secondary stages: primary hemostasis involves vascular
constriction, platelet activation and aggregation; and
secondary hemostasis involves the activation of coagulation
cascade, clot formation, and the clot dissolution by fibri-
nolysis. The coagulation cascade is composed of intrinsic
and extrinsic pathways that lead to the activation of
different coagulatory factors.1 Both cascades converge at
the activation of factor X (generating factor Xa, ‘a’ signifies
active). Factor Xa forms a complex with factor Va to acti-
vate prothrombin to become thrombin. Thrombin then
converts fibrinogen to a fibrin network. Afterwards, fibri-
nolysis is triggered by activation of plasminogen to plasmin
by tissue plasminogen activator (tPA) or urokinase to
prevent thrombosis. Both coagulation and fibrinolysis are
regulated by feedback inhibition as well as inhibitors. In
addition to inducing fibrin formation, thrombin can also
bind to thrombomodulin (TM) on endothelial cell surface, to
activate protein C (APC), which is able to inactivate factor
VIIIa and Va, thus preventing further thrombin generation.2
Under normal conditions, fibrinolysis is also tightly regu-
lated. Excessive activation of the fibrinolysis will lead to an
increasing tendency for bleeding, whereas inhibition of the
fibrinolysis will result in thrombosis. Type-I plasminogen
activator inhibitor (PAI-1) is the principal inhibitor of tPA
and urokinase, which play an important role in the control
of the fibrinolytic system. APC can also inactivate PAI-I to
enhance the fibrinolysis. Therefore, the balance between
coagulation and fibrinolysis is very important and delicately
controlled in vivo.
Hemostasis is also tightly linked to inflammation. Both
systems are interrelated as part of the innate host defense
mechanism and show a two-way crosstalk between each
other.3,4 Inflammation induced during infection generally
shifts the hemostatic mechanism toward thrombosis by up-
regulation of procoagulant factors, down-regulation of
anticoagulants and inhibit fibrinolytic activity.5 However,
coagulation product such as thrombin also has a variety of
activities on cells that result in augmentation of the
inflammatory response. In addition, anticoagulatory mole-
cules such as APC possess not only anticoagulatory activity,
but also antiinflammatory activity.2 However, infection
with certain viruses can tilt the hemostasis toward bleeding
and cause viral hemorrhage fever (VHF).6,7 Among VHFs,
dengue, Marburg, and Ebola are the most important ones
and dengue virus (DENV) infection is the most prevalent.8
More than 2.5 billion people, or half of the world’s pop-
ulation in tropical and subtropical countries including
Southeast Asia and Taiwan are at the risk of DENV
infection.9
DENV is a mosquito-borne flavivirus that is transmitted
by mosquitoes such as Aedes aegypti or Aedes albopictus.
DENV is a positive-stranded RNA with envelope.8 It
composes of three structural proteins including core
protein (C); membrane-associated protein (M) produced as
a precursor protein (prM); envelope protein (E) and sevennonstructural proteins (NS). Based on the antigenic differ-
ence of E protein, DENV can be divided into four different
serotypes, DENV 1e4. DENV infection might lead to an
influenza-like illness, which is called dengue fever or cause
more severe dengue hemorrhage fever (DHF) or dengue
shock syndrome (DSS). DHF is a severe febrile disease
characterized by abnormalities in homeostasis and
increased capillary leakage that can progress to blood
pressure decrease, and hypovolemic shock (DSS).10
Although DHF/DSS can be seen during primary infection,
it occurs more frequently following second infection with
a different serotype of DENV from that of previous infec-
tion. Therefore, it is generally believed that immunopa-
thogensis is involved in DHF/DSS. Different hypotheses have
been proposed to explain the pathogenesis of DHF/DSS
including overproduction of proinflammatory cytokines,
aberrant immune activation, and antibody-dependent
enhancement (ADE).11e13 Among them, the theory of ADE
plays a central role. Based on ADE, antibodies that are
generated in previous DENV infection may enhance DENV of
different serotypes to infect macrophage through Fcg
receptor. However, neither cytokine storm nor ADE can
explain why hemorrhage occurs in DHF/DSS patients. A
better understanding of the mechanism to induce hemor-
rhage by DENV is required to develop a more effective and
specific therapy against the development of DHF/DSS.
In almost all DHF patients, defects of coagulation acti-
vation such as a prolonged activated partial thromboplastin
time (APTT) or thrombin time can be found. In addition,
a decreased fibrinogen level and increased levels of
fibrinogen degradation products indicating hyperfibrinolysis
may also occur in DHF/DSS patients.14e16 Therefore, DENV
infection not only causes the defect in the activation of
coagulation but also the acceleration of fibrinolysis. The
pathogenic effects of some of the possible factors that may
contribute to the disturbance of the tightly regulated
coagulation and fibrinolysis during DENV infection are dis-
cussed in this review.Autoantibodies against coagulatory and
fibrinolytic molecules induced by DENV
through molecular mimicry
Based on computer sequence comparison between DENV
proteins and coagulatory molecules, there are at least 12
different regions of DENV proteins, including core, prM, E,
and NS1 proteins, that have amino acid sequence similarity
with different coagulatory molecules, such as factors X, XI,
and VII.17 The molecular mimicry between DENV proteins
and coagulation and fibrinolysis factors may induce auto-
antibodies that can interfere with the hemostasis. The first
report indicating that there are autoantibodies against
coagulation factor in dengue patients, was published by
Markoff et al.18 They found that Type 4 DENV E protein
amino acid 100e119 (D4E; GWGNGCGLFGKGVVTCAKF)
shares sequence homology with plasminogen amino acid
759e779 (PLþ; SWGLGCARPNKPGVYVRVSRF). They also
found that antibodies cross-reacting to PLþ peptide in
dengue patients were correlated to hemorrhage.19 In
a previous study, we proved that D4E peptide can induce
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inhibit plasmin activity in vitro. However, the exact effect
of plasminogen binding antibodies on its activation is still
unclear due to the heterogeneity of antibodies in anti-
sera.20 Recently, we have generated several monoclonal
antibodies from DENV immunized mice. Some of them
(6H11, 7D2, 8E5, 2A12) could cross-react with plasminogen
and enhance its activation.21 The fibrinolysis in 6H11-
injected mice was also increased as compared with that in
control IgG-injected mice. Thus, these plasminogen cross-
reactive DENV antibodies may play a role in causing the
hyperfibrinolysis during DENV infection. In addition, a single
chain fragment of variable region (scFv) generated from
NS1 immunized mice could bind to fibrinogen and prolonged
clot formation.17 Furthermore, anti-thrombin antibodies
that could inhibit its activity are also found in dengue
patients’ sera (unpublished data). Therefore, autoanti-
bodies that can cross-react with several different coagu-
lation factors and interfere with their functions are induced
during DENV infection. Autoantibodies that can cross-react
to factors IX, X, VII, and VIII, prothrombin, thrombin, and
plasmin are also found in antiphospholipid syndrome (APS)
patients.22e26 However, in contrast to dengue patients,
autoantibodies in APS patients can inhibit plasmin activity
and enhance prothrombin activation, which may lead to
thrombosis in APS patients. Therefore, it is likely that,
based on the difference of the specificities, autoantibodies
against coagulatory and fibrinolytic factors may have
different influences on coagulation and fibrinolysis
activation.
In addition to the cross-reactivity with coagulatory and
fibrinolytic factors, antibodies against DENV can also cross-
react with endothelial cells, platelets, and hepatocytes,
which may contribute to thrombocytopenia, vascular
leakage, and liver damage in DHF/DSS.27e30 Therefore, in
addition to ADE, antibodies against DENV play several other
roles in the immunopathogenesis of DHF/DSS, which may
involve different mechanisms to cause the manifestation of
hemorrhage in DENV infection.Influence of cytokines induced by DENV on
coagulation and fibrinolysis
Many proinflammatory cytokines and chemokines are
increased in dengue patients, including macrophage
migration inhibitory factor (MIF).31e33 The sera level of MIF
is correlated with the severity and the mortality of dengue
patients.33 In addition, DENV infection of different cells
induced MIF secretion.34,35 MIF is a proinflammatory cyto-
kine that can induce the expression and secretion of other
cytokines, chemokines, and adhesion molecules including
tumor necrosis factor-a, interleukin-1b, vascular cell
adhesion molecule-1, intracellular cell adhesion molecule-
1, matrix metalloproteinases, and vascular endothelial
growth factor.36e38 Cytokines such as tumor necrosis factor-
a and interleukin-1b induced by MIF can promote the
synthesis of platelet-activating factor (PAF). PAF is a phos-
pholipid activator and mediator of leukocyte functions
including platelet aggregation and inflammation. The
essential role of PAF in the pathogenesis of DENV infection
has been demonstrated by PAF receptor knockout mice,which show decreased thrombocytopenia, hemoconcen-
tration, decreased systemic levels of cytokines, and delay
of lethality after DENV infection, when compared with the
wild-type mice.39 Furthermore, the importance of MIF in
DENV-induced coagulopathy and lethality of mice was also
demonstrated by Iranaia Assunc¸a˜o-Miranda et al in MIF
knockout mice.34 Reduced thrombocytopenia, plasma
leakage, and proinflammatory response are found in MIF
knockout mice as compared with the wild-type mice after
DENV infection. Using recombinant MIF as well as the
supernatants from DENV-infected cells, we confirmed that
MIF can enhance the permeability of endothelial cells,
which may contribute to plasma leakage in vivo.35 In
addition, MIF can induce intracellular cell adhesion
molecule-1 and thrombomodulin expression of endothelial
cells in vitro.40 Recently, we also found that MIF can induce
cell autophagy which may enhance DENV replication.41,42
Thus, cytokines such as MIF induced by DENV infection
may participate in the hemostatic defect in DHF/DSS
patients.Aberrant expression of tPA and TM in DENV-
infected or -stimulated cells
Due to the fact that the pathogenic changes of vascular
leakage and coagulopathy in DHF/DSS are reversible, it is
generally believed that physical damage is not involved in
DENV-infected endothelial cells. Instead, soluble media-
tors such as cytokines produced during the acute phase of
infection are likely to play an important role in the
pathogenesis of DHF/DSS. However, cytokines are
nonspecific and can be induced by other viral infections
that do not lead to vascular leakage. In addition, as we
mentioned earlier, autoantibodies induced by DENV may
cross-react with endothelial cells, platelets, and coagu-
latory factors, which may contribute to the pathogenesis
of DHF/DSS. However, antibodies are generally induced
a week after infection. Thus, we think the direct patho-
genic roles of DENV or its products cannot be neglected,
especially in the early stage of DENV infection. In the
early stage of DENV infection, in addition to the APTT
prolongation, the fibrinolytic parameters such as tPA and
PAI-1 in dengue patients sera are also increased.15,43 The
increased tPA/PAI-1 ratio in dengue patients may prone
the activation of fibrinolysis in these patients.15 In addi-
tion, endothelial cells infected with DENV showed
increased tPA expression whereas the expression of PAI-1
showed no difference after infection.44,45 However, PAI-1
gene expression in human hepatoma cell line, HuH-7 is
increased after incubation with purified recombinant
DENV E protein domain III (DIIIE).46 Therefore, both DENV
infection and its protein stimulation can affect the
expression of hemostasis-related molecules on different
cells. Similar effects of DENV on the expression of TM on
human endothelial cells in vitro are also found.45,47,48 TM
expressed on the surface of endothelial cells and mono-
cytes is very important in the activation of protein C,
which is important to the negative regulation of blood
coagulation. The activation of protein C by thrombin-TM
complex is augmented when it binds to endothelial cell
protein C receptor (EPCR).2,49 Once APC dissociates
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surfaces and inactivate factors Va and VIIIa, thereby
inhibiting further thrombin generation. Therefore, TM
plays an important role in the anticoagulant state of
endothelium. The sera level of secreted TM is increased in
dengue patients.50 In addition, the expressions of several
other protein C-activation-related molecules such as
EPCR and protein S are also increased in DV-infected
endothelial cells. The increased expression of TM, EPCR,
and protein S in DV-infected EC may enhance protein
C activation and lead to rapid thrombin inactivation,
which may contribute to the hemorrhage in dengue
patients. Taken together, DENV infection or its protein
stimulation can promote the expression of anticoagulant
molecules expression on endothelial cells, which
may contribute to the anticoagulant properties of
these cells and increase the hemorrhagic risk in DENV
patients.Inhibition of prothrombin activation by DENV
NS1 proteins
During DENV infection, NS1 can be present in three
different forms: intracellular, extracellular, and membrane
forms. The extracellular form of NS1 is secreted as a soluble
hexamer, which is also known as secreted NS1 (sNS1).Figure 1 The sequence of events leading to dengue hemorrha
secreted nonstructural protein 1 (NS1), macrophage migration in
autoantibodies in dengue hemorrhage fever (DHF) or dengue s
common complications (upper panel), and possible mechanistic cau
shown. NS1 protein secreted during early stage of DENV infection b
points, MIF induced by DENV infection may enhance DENV replicat
leakage through tight junction disruption. Finally, the production o
inhibit coagulation and enhance fibrinolysis in dengue patients toRecently, it was found that sNS1 can form a lipoprotein
particle with an open-barrel protein shell and a prominent
central channel rich in lipids.51 The detection of sNS1 in
patients’ sera not only provides a rapid diagnosis for DENV
infection, but also the sera levels of sNS1 in dengue
patients are correlated with the disease severity.52 In
addition, sNS1 can bind to heparin sulfate and chondroitin
sulfate E on the endothelial cell surface. The binding of
sNS1 to endothelium and its subsequent recognition by anti-
NS1 antibodies may also contribute to the vascular leakage
in DHF/DSS.53 However, the direct pathogenic role of sNS1
is still unclear. Recently it was found that sNS1 can interact
with complement and play a role in protecting DENV from
complement-dependent opsonization.54,55 Using recombi-
nant NS1, we found NS1 can bind to both thrombin and
prothrombin.56 Even though the thrombin activity is not
altered when NS1 binding to thrombin, the binding of NS1 to
prothrombin can inhibit its activation, which may
contribute to the prolongation of APTT in dengue
patients.56 This may explain why APTT abnormality occurs
within the 1st week of fever onset when antibodies are still
underdeveloped.57 In addition, since the vascular leakage
in dengue patient is also directly related to APTT levels,57
NS1 may also contribute to plasma leakage by mecha-
nisms without antibody involved. These results suggest that
DENV sNS1 plays a direct and important role in the vascular
leakage and hemorrhage in DHF/DSS.ge and the possible pathogenic roles of dengue virus (DENV)
hibitory factor (MIF), and coagulation factors cross-reactive
hock syndrome (DSS). The timing of clinical symptoms and
ses (lower panel) following mosquito bite in dengue patients are
inding to prothrombin may inhibit its activation. At later time
ion through autophagy, which may also contribute to vascular
f coagulation factors cross-reactive autoantibodies may further
cause bleeding.
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Hemorrhage induced by DENV infection may involve both
viral factors and host factors. Viral factors such as virus
infection, viral sNS1 and DIIIE proteins can affect coagula-
tion in direct or indirect manners. Host factors such as
cytokines and autoantibodies induced by DENV may also
play a role in the disruption of the balance of coagulation
and fibrinolysis as well as in the functions of endothelial
cells and platelets. It is the combination of both viral and
host factors that may cause the hemorrhage in DHF/DSS.
Therefore, besides the direct pathogenic effects of DENV to
cells, we propose that viral sNS1, MIF, and coagulation
cross-reactive autoantibodies may also play important roles
in the pathogenesis of DHF/DSS (Fig. 1). Each of them may
play different pathogenic roles in different stages of DENV
infection. Blockage of sNS1or MIF may provide alternative
approaches to prevent the development of DHF/DSS.
Moreover, epitopes mimic to coagulation factors should be
avoided in the design of dengue vaccines to prevent
possible side effects.
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